Diagnosis and treatment of ovarian hyperstimulation syndrome after assisted reproductive technology

doi:10.3877/cma.j.issn.2095-3259.2020.01.008

Abstract

Abstract:

Ovarian hyperstimulation syndrome (OHSS) is the most common complication of assisted reproductive techniques(ART), pregnancy can aggravate OHSS and even endanger women′s life safety. Therefore, active prevention, close monitoring and timely treatment are needed to avoid the serious consequences of ovarian hyperstimulation syndrome.

Key words: Assisted reproductive technique, Pregnancy, Ovarian hyperstimulation syndrome

Yiping Zhong, Jiahui Xu. Diagnosis and treatment of ovarian hyperstimulation syndrome after assisted reproductive technology[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2020, 09(01): 31-35.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2020.01.008

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/31

Figures/Tables 1

References 32

[1]	Nouri K, Tempfer CB, Lenart C, et al. Predictive factors for recovery time in patients suffering from severe OHSS[J]. Reprod Biol Endocrinol, 2014, 12(1): 1-8.
[2]	Xu GF, Zhou CL, Xiong YM, et al. Reduced Intellectual Ability in Offspring of Ovarian Hyperstimulation Syndrome: A Cohort Study[J]. EBioMedicine, 2017, 20: 263-267.
[3]	Macdougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome[J]. Hum Reprod, 1992, 7(5): 597-600.
[4]	Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews[J]. Cochrane Database Syst Rev, 2017, 1(2): CD012103.
[5]	Palumbo A, Avila J, Naftolin F. The Ovarian Renin-Angiotensin System (OVRAS): A Major Factor in Ovarian Function and Disease[J]. Reprod Sci, 2016, 23(12): 1644-1655.
[6]	Zhai J, Liu J, Cheng X, et al. Zinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1)[J]. Sci Rep, 2017, 7(1): 3245.
[7]	Ocal P, Sahmay S, Cetin M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles[J]. J Assist Reprod Genet, 2011, 28(12): 1197-1203.
[8]	Lee TH, Liu CH, Huang CC, et al. Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles[J]. Hum Reprod, 2007, 23(1): 160-167.
[9]	Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline [J]. Fertil Steril, 2016, 106(7): 1634-1647.
[10]	Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors [J]. Hum Reprod, 1994, 9(5):792.
[11]	Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures[J]. Hum Reprod Update, 2003, 9(3): 275-289.
[12]	Luke B, Brown MB, Morbeck DE, et al. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome[J]. Fertil Steril, 2010, 94(4): 1399-1404.
[13]	Xu CK, Tang SB. Alteration of endometrial receptivity in rats with ovarian hyperstimulation syndrome[J]. J Obstet Gynaecol, 2014, 34(2):146-152.
[14]	Mahajan N, Gupta S, Sharma S, et al. Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis[J]. J Hum Reprod Sci, 2016, 8(4): 234-238.
[15]	Delvigne Annick, Rozenberg Serge. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review[J]. Human Reproduction Update, 2002(6): 6.
[16]	Davenport WB, Kutteh WH. Inherited Thrombophilias and Adverse Pregnancy Outcomes. A Review of Screening Patterns and Recommendations[J]. Obstet Gynecol Clin North Am, 2014, 41(1): 133-144.
[17]	Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome？[J]. BJOG, 2000, 107(8): 943.
[18]	Courbiere B, Oborski V, Braunstein D, et al. Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control study[J]. Fertil Steril, 2011, 95(5): 1629-1632.
[19]	乔杰. 生殖医学临床诊疗常规[M]. 北京：人民军医出版社，2013.
[20]	Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study [J]. Fertil Steril, 1998, 70(6): 1070-1076.
[21]	Haas J, Baum M, Meridor K, et al. Is severe OHSS associated with adverse pregnancy outcomes? Evidence from a case-control study[J]. Reprod Biomed Online, 2014, 29(2): 216-221.
[22]	Jelliffe-Pawlowski LL, Shaw GM, Currier RJ, et al. Association of early-preterm birth with abnormal levels of routinely collected first- and second-trimester biomarkers[J]. Am J Obstet Gynecol, 2013, 208(6): 492.e1-492.e11.
[23]	Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No.268, November 2011[J]. Int J Gynaecol Obstet, 2012, 116(3): 238-273.
[24]	Khong TY, De Wolf F, Robertson WB, et al. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants[J]. BJOG, 1986, 93(10): 1049-1059.
[25]	Vinayak S, Tiki O, Beverley V. Prevention of Ovarian Hyperstimulation Syndrome: A Review[J]. Obstet Gynecol Int, 2015, 2015: 514159.
[26]	Naredi N, Singh SK, Lele P, et al. Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach？[J]. Med J Armed Forces India, 2018, 74(1): 44-50.
[27]	Bahia N, Mohammad E, Zahra S et al. Ovarian hyperstimulation syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management[J]. Iran J MED Sci, 2018, 43(3): 248-260.
[28]	杨硕，何艺磊，梁靓，等. 促性腺激素释放激动剂联合低剂量人绒毛促性腺激素扳机在高反应患者体外受精治疗中的应用[J]. 中华生殖与避孕杂志，2018, 38(3): 181-635.
[29]	Ho VNA, Braam SC, Pham TD, et al. The effectiveness and safety of in vtro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count[J]. Hum Reprod, 2019, 34(6): 1055-1064.
[30]	Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J]. Fertil Steril, 2015，104: 52-72.
[31]	Nardo LG, Cheema P, Gelbaya TA, et al. The optimal length of coasting protocol′ in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization [J]. Human Fertility, 2006, 9(3): 175-180.
[32]	Jun SJ, Yeonseong J, Eunjee N, et al. Clinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome[J]. Obstet Gynecol Sci, 2018, 61(4): 497-504.

病情程度	临床表现	实验室检查
轻度	腹胀/不适；轻度恶心/呕吐；轻度呼吸困难；腹泻；卵巢增大	无明显变化
中度	腹部症状(包括腹胀、纳差、轻度恶心及呕吐)；卵巢增大；超声证实腹水存在	红细胞压积>41%，白细胞>15×10⁹/L
重度	有轻到中度的腹部症状；临床证实存在腹水、胸腔积液；呼吸困难；少尿或无尿；顽固性恶心和(或)呕吐	红细胞压积>55%，白细胞>25×10⁹/L，肌酐清除率<50 ml/min，肌酐>1.6 mg/dl，血钠<135 mmol/L，血钾>5 mmol/L，肝酶升高
危重	低血压或低中心静脉压；胸腔积液和(或)心包积液；体重增加>1 kg/24 h；晕厥；严重腹痛；静脉栓塞；动脉血栓形成；无尿、急性肾功能衰竭；心律失常；成人呼吸窘迫综合征；脓毒血症	(以上实验室指标进一步恶化)

病情程度	临床表现	实验室检查
轻度	腹胀/不适；轻度恶心/呕吐；轻度呼吸困难；腹泻；卵巢增大	无明显变化
中度	腹部症状(包括腹胀、纳差、轻度恶心及呕吐)；卵巢增大；超声证实腹水存在	红细胞压积>41%，白细胞>15×10⁹/L
重度	有轻到中度的腹部症状；临床证实存在腹水、胸腔积液；呼吸困难；少尿或无尿；顽固性恶心和(或)呕吐	红细胞压积>55%，白细胞>25×10⁹/L，肌酐清除率<50 ml/min，肌酐>1.6 mg/dl，血钠<135 mmol/L，血钾>5 mmol/L，肝酶升高
危重	低血压或低中心静脉压；胸腔积液和(或)心包积液；体重增加>1 kg/24 h；晕厥；严重腹痛；静脉栓塞；动脉血栓形成；无尿、急性肾功能衰竭；心律失常；成人呼吸窘迫综合征；脓毒血症	(以上实验室指标进一步恶化)

Please choose a citation manager

Content to export